In a phase 2 study we aimed to assess the efficacy and safety of grazoprevir ( MK-5172 ; HCV NS3/4A protease inhibitor ) and two doses of elbasvir ( MK-8742 ; HCV NS5A inhibitor ) in patients with HCV mono-infection and HIV/HCV co-infection .